关于阿尔茨海默病药理治疗的最新信息
1Department of Neurology, Mayo Clinic, Jacksonville, Florida, United States. tipton.philip@mayo.edu.
Neurologia i neurochirurgia polska
|August 22, 2023
概括
新的阿尔茨海默病疗法显示出希望,三种单克隆抗体显示出积极的III期试验结果. 需要进一步的研究来确认临床益处与患者和医疗保健系统的风险.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默氏症 (AD) 是导致痴呆的主要原因,构成了全球重大健康挑战.
- 目前的AD治疗提供有限的益处,并且没有治愈疗法存在.
- 粉样β (Aβ) 假设,专注于斑块形成,指导了治疗的发展.
研究的目的:
- 为提供阿尔茨海默病最近疾病修饰疗法的概述.
- 更新已达到III期临床试验的疗法.
- 帮助临床医生做出决策,并为患者提供有关AD新疗法的咨询.
主要方法:
- 对阿尔茨海默病治疗方法的第三期临床试验数据的审查.
- 专注于针对粉样β斑块发展的单克隆抗体.
- 对最近的积极试验结果的分析.
主要成果:
- 三种单克隆抗体 (aducanumab,lecanemab,donanemab) 在第三阶段试验中显示出积极的结果.
- 这些疗法针对的是粉样β斑块积累路径.
- 尽管取得了积极的结果,但仍然存在关于临床有效性和风险/益处概况的疑问.
结论:
- 最近在单克隆抗体方面的进展为阿尔茨海默病治疗提供了潜在的突破.
- 进一步评估至关重要,以确定这些新疗法的临床效用和医疗保健影响.
- 更新的信息对于临床医生来说至关重要,以有效指导患者的护理和咨询.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.5K
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
1.4K
相关概念视频
01:22Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
01:26Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
152
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
152
01:28Drug Therapy
68
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
68
01:24Parkinson's Disease: Treatment
297
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
297
01:23Antidepressant Drugs: MAOIs and Other Agents
272
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
272